Ryosuke Sato, Tania Garfias-Veitl, Angelika Hafke, Andreas Fischer, Guglielmo Fibbi, Mirela Vatic, Breno Wozne, Constanze Schmidt, Jürgen Kolos, Max Diesner, Thomas Bernd Dschietzig, Goran Loncar, John G F Cleland, Stefan D Anker, Stephan von Haehling
{"title":"Iron Deficiency and Bone Metabolism in Heart Failure.","authors":"Ryosuke Sato, Tania Garfias-Veitl, Angelika Hafke, Andreas Fischer, Guglielmo Fibbi, Mirela Vatic, Breno Wozne, Constanze Schmidt, Jürgen Kolos, Max Diesner, Thomas Bernd Dschietzig, Goran Loncar, John G F Cleland, Stefan D Anker, Stephan von Haehling","doi":"10.1093/ejhf/xuag259","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Iron deficiency (ID) is common in chronic heart failure (HF) and may disturb bone metabolism.We investigated the association of ID with bone mineral density (BMD), and the potential mediating roles of fibroblast growth factor 23 (FGF-23) and 1,25-dihydroxy vitamin D (1,25(OH)2 vitamin D) in patients with chronic HF from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).</p><p><strong>Methods and results: </strong>ID was defined as a transferrin saturation (TSAT) <20%. Among 198 patients (69 [61-76] years, 80% men), TSAT was <20% in 29.8% and associated with higher BMD (1.25 vs. 1.20 g/cm2, p=0.009), with a graded dose-response across TSAT quartiles (p for trend=0.0009). ID was also associated with higher serum FGF-23 (pg/mL; adjusted β=0.20, p=0.0009) and lower plasma 1,25(OH)2 vitamin D (30 vs. 35 pg/mL, p=0.03). In multivariable analyses, both TSAT <20% (adjusted odds ratio (aOR) 3.45, p=0.01) and lower plasma 1,25(OH)2 vitamin D (aOR 0.54, p=0.002) were associated with BMD above sex-specific medians.</p><p><strong>Conclusions: </strong>In HF, a TSAT <20% is associated with disturbed bone metabolism, possibly mediated by increases in serum FGF-23 and reductions in 1,25(OH)2 vitamin D concentrations. Detailed analyses of bone microstructure in HF are warranted.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3000,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ejhf/xuag259","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: Iron deficiency (ID) is common in chronic heart failure (HF) and may disturb bone metabolism.We investigated the association of ID with bone mineral density (BMD), and the potential mediating roles of fibroblast growth factor 23 (FGF-23) and 1,25-dihydroxy vitamin D (1,25(OH)2 vitamin D) in patients with chronic HF from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
Methods and results: ID was defined as a transferrin saturation (TSAT) <20%. Among 198 patients (69 [61-76] years, 80% men), TSAT was <20% in 29.8% and associated with higher BMD (1.25 vs. 1.20 g/cm2, p=0.009), with a graded dose-response across TSAT quartiles (p for trend=0.0009). ID was also associated with higher serum FGF-23 (pg/mL; adjusted β=0.20, p=0.0009) and lower plasma 1,25(OH)2 vitamin D (30 vs. 35 pg/mL, p=0.03). In multivariable analyses, both TSAT <20% (adjusted odds ratio (aOR) 3.45, p=0.01) and lower plasma 1,25(OH)2 vitamin D (aOR 0.54, p=0.002) were associated with BMD above sex-specific medians.
Conclusions: In HF, a TSAT <20% is associated with disturbed bone metabolism, possibly mediated by increases in serum FGF-23 and reductions in 1,25(OH)2 vitamin D concentrations. Detailed analyses of bone microstructure in HF are warranted.
期刊介绍:
European Journal of Heart Failure is an international journal dedicated to advancing knowledge in the field of heart failure management. The journal publishes reviews and editorials aimed at improving understanding, prevention, investigation, and treatment of heart failure. It covers various disciplines such as molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, clinical sciences, social sciences, and population sciences. The journal welcomes submissions of manuscripts on basic, clinical, and population sciences, as well as original contributions on nursing, care of the elderly, primary care, health economics, and other related specialist fields. It is published monthly and has a readership that includes cardiologists, emergency room physicians, intensivists, internists, general physicians, cardiac nurses, diabetologists, epidemiologists, basic scientists focusing on cardiovascular research, and those working in rehabilitation. The journal is abstracted and indexed in various databases such as Academic Search, Embase, MEDLINE/PubMed, and Science Citation Index.